Advertisement
Home »

Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies.

Jan 08, 2024

ABOUT THE EXPERTS

  • Nick H Kim

    UC San Diego Health, Division of Pulmonary, Critical Care, and Sleep Medicine, University of California San Diego, 9300 Campus Point Dr, La Jolla, CA, 92037-7381, USA. h33kim@ucsd.edu.

    Kelly M Chin

    UT Southwestern Medical Center, Dallas, TX, USA.

    Vallerie V McLaughlin

    University of Michigan, Ann Arbor, MI, USA.

    Hilary DuBrock

    Mayo Clinic, Rochester, MN, USA.

    Ricardo Restrepo-Jaramillo

    University of South Florida, Tampa, FL, USA.

    Zeenat Safdar

    Houston Methodist, Weill Cornell Medical College, Houston, TX, USA.

    Gwen MacDonald

    Global Medical Affairs, Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson and Johnson, Allschwil, Switzerland.

    Nicolas Martin

    Statistical Decision Science, Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson and Johnson, Allschwil, Switzerland.

    Daniel Rosenberg

    Global Epidemiology, Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson and Johnson, Allschwil, Switzerland.

    Maria Solonets

    Global Medical Safety, Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson and Johnson, Allschwil, Switzerland.

    Richard Channick

    David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement